HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RDHL
RedHill Biopharma Ltd.
There isn't enough reported data to score RDHL yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RDHL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
RDHL's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RDHL PE Valuation
RDHL has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RDHL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect RDHL's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RDHL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2023 | $0.25 | +$120.25 |
| Q2 2023 | -$59.00 | +$99.35 |
| Q4 2022 | -$120.00 | +$98.35 |
| Q2 2020 | -$300.00 | -$153.15 |
| Q4 2019 | -$280.00 | -$103.15 |
| Q4 2018 | -$176.85 | +$83.15 |
| Q4 2017 | -$260.00 | +$890.00 |
RDHL has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RDHL in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
RDHL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $4.1M | +59% |
| Q4 2024 | $5.5M | +382% |
| Q2 2024 | $2.6M | -52% |
| Q4 2023 | $1.1M | -96% |
| Q2 2023 | $5.4M | -83% |
| Q4 2022 | $30.4M | -31% |
| Q2 2022 | $31.5M | -25% |
| Q4 2021 | $43.7M | +3% |
RDHL's revenue has slid since its 2021 peak: $4M last quarter, down 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -107% | -565 points |
| Q4 2024 | -113% | -57 points |
| Q2 2024 | -328% | -247 points |
| Q4 2023 | -1061% | -974 points |
| Q2 2023 | 457% | +560 points |
| Q4 2022 | -56% | +24 points |
| Q2 2022 | -82% | +52 points |
| Q4 2021 | -87% | +635 points |
RDHL's operating margin was −107% last quarter, down 565 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
RDHL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | -$5M | +$1.2M |
| Q4 2024 | -$3.2M | +$14.9M |
| Q2 2024 | -$6.2M | +$11.6M |
| Q4 2023 | -$18M | -$9.6M |
| Q2 2023 | -$17.8M | +$3.1M |
| Q4 2022 | -$8.5M | +$25.4M |
| Q2 2022 | -$20.9M | +$10.3M |
| Q4 2021 | -$33.9M | -$11.8M |
RDHL has burned cash in almost every quarter: −$32M over the past year, against −$81M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RDHL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RDHL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9252% | +50.6M shares |
| 1 year | +13933% | +50.8M shares |
| 3 years | +200407% | +51.1M shares |
RDHL has 51M diluted shares, up 13933% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2016 | — |
| Q3 2016 | — |
| Q2 2016 | — |
| Q1 2016 | — |
| Q4 2015 | — |
| Q3 2015 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RDHL Net Leverage
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RDHL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.9 | Neutral |
| Stochastic | 2.1 | Oversold |
RDHL's weekly RSI is 31 (neutral) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RDHL PE vs Healthcare Sector
RDHL has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RDHL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.45 | 16% below |
| 20 week MA | $0.58 | 34% below |
| 50 week MA | $0.84 | 55% below |
| 100 week MA | $1.75 | 78% below |
| 200 week MA | $20.6 | 98% below |
RDHL is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over RDHL on returns for 2026, with the stronger performance.
RDHL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6,050.0 | $9,320.0 | +54% |
| 2021 | $9,320.0 | $2,640.0 | -72% |
| 2022 | $2,640.0 | $158.5 | -94% |
| 2023 | $158.5 | $36.5 | -77% |
| 2024 | $36.5 | $6.91 | -81% |
| 2025 | $6.91 | $1.14 | -84% |
| 2026 YTD | $1.14 | $0.38 | -67% |
RDHL has finished five years in a row lower, and it's down 67% so far in 2026.